Cypherpunk Technologies

CYPH on Nasdaq. Pharmaceutical preparations. Market value $342m.

Watch this stockFree. We tell you when something changes.

Price checks use the past 12 months to June 2026. Some use the latest annual report instead, as marked. Quality checks use five annual reports, the latest for the year to December 2025.

We can't read total debt from the filing, so debt is left out.

Cash flow or capital spending isn't reported, so free cash flow is unknown.

Should I look at this?

Look carefully before going further

Read the warning sign in its own filings

This is not advice. Check the numbers below.

Compare with another stock

Cash yield
annual report to December 2025
n/a

We could not compute this from the filings.

Price to profit
past 12 months to June 2026
n/a

The filings do not give us enough to work this out.

Return on capital
five annual reports to December 2025
n/a

The filings do not give us enough to work this out.

Quality score: not known. Price score: 16 of 100. Our list needs 70 on quality and 60 on price.

$3.17 a share, 707% above its 1-year low

Over the past year the price has ranged from $0.39 to $4.19.

Pays no dividend

Prices from Monday’s close (5 October).

Five years of cash, in billions

n/a
n/a
n/a
n/a
n/a
20212022202320242025
Revenue
$2mn/an/an/an/a
Operating margin
-2761.7%n/an/an/an/a
Debt to equity
n/an/an/an/an/a
Shares outstanding
0.10bn0.03bn0.04bn0.06bn0.11bn

Health checks

  • Free cash flow positiveNot enough data
  • Accounting looks honest (Beneish)Not enough data
  • Financial strength (Piotroski)Not enough data
  • Profit backed by cash (accruals)No
  • DebtUnknown
  • Revenue growth, five yearsUnknown
  • Buying back its own sharesNo, 9% more shares since 2021

The quarter to June 2026

How the business did, compared with the same quarter a year earlier.

  • Profit: $39 million, after a loss of $17 million a year ago.
  • 424% more shares than a year ago. Each share owns a bit less of the company.
Profit by quarter
Profit by quarter
Quarter toAmount
September 2024-$18m
December 2024-$15m
March 2025-$15m
June 2025-$17m
September 2025-$3m
December 2025$40m
March 2026-$77m
June 2026$39m

From the company's quarterly reports to the SEC.

Dates

Next results (estimated)
n/a
Last annual report (10-K)
16 March 2026
Next quarterly (estimated, 10-Q)
11 November 2026

Who owns it

None of the long-term investors we follow own it. 47 funds in all.

Jun '25
Dec '25
Jun '26
Largest holders overall

From 13F filings for the quarter ended 30 June 2026.

Big holders and activists

2 investors own more than 5%.

  • Winklevoss Capital Fund, LLC
    at least 19.9%0.0 pts
    (filed with 4 related holders)
    Since 17 August 2026
  • Severns Sean Michael
    Passive investor
    10.6%
    Since 12 November 2025
  • GILEAD SCIENCES, INC.
    Passive investor
    Sold down below 5%
    Since 31 December 2025
  • Samsara BioCapital, L.P.
    Passive investor
    Sold down below 5%
    Since 30 June 2025
  • Sold down below 5%
    Since 31 December 2024

From Schedule 13D and 13G filings: anyone owning more than 5% must file one.

What insiders did

No insider bought shares on the open market in the last 12 months. 6 sold $6m.

  • Oei Khing Djien
    Director
    Sold
    Date
    25 September 2026
    Shares
    168,750
    Price
    $3.92
    Value
    $661,500
  • Martin Patricia A.
    Director
    Sold
    Date
    23 September 2026
    Shares
    50,000
    Price
    $3.86
    Value
    $193,000
  • Dietz Thomas John
    Director
    Sold
    Date
    26 August 2026
    Shares
    20,000
    Price
    $1.72
    Value
    $34,400
  • Mirabelli Christopher
    Director
    Sold
    Date
    26 March 2026
    Shares
    60,000
    Price
    $0.71
    Value
    $42,600
  • Mirabelli Christopher
    Director
    Sold
    Date
    17 November 2025
    Shares
    676,319
    Price
    $3.14
    Value
    $2m
  • CAVANAUGH JAMES H
    Director
    Sold
    Date
    17 November 2025
    Shares
    261,840
    Price
    $3.14
    Value
    $822,178
  • ONSI DOUGLAS E
    CEO,CFO,Pres.,GC,Treas.&Sec., Director
    Sold
    Date
    17 November 2025
    Shares
    676,319
    Price
    $3.14
    Value
    $2m

From Form 4 filings: insiders must report trades in their own company's shares within two days.

Warning signs in its filings

Problems the company itself reported to the SEC, in its own words.

1 serious warning sign in Cypherpunk Technologies’ filings.

We look for five warning signs: doubt it can keep going, weak checks on its own accounts, a notice that its past accounts can't be relied on, a change of auditor, and one customer bringing in a big share of sales. We don't check lawsuits, investigations or debt yet.

We checked the auditor's report, internal controls, restatement notices, auditor changes and big customers in the 10-K filed 16 Mar 2026, plus the 10-Q filed 12 Aug 2026 and 9 later 8-Ks.

  • Weak checks on its own accounts

    Serious

    The company said its checks on its own accounts did not work at the end of its latest quarter. Mistakes could slip into the numbers.

    “Because this material weakness remained unremediated as of June 30, 2026, management concluded that our disclosure controls and procedures were not effective as of that date.”
    Show the full paragraph
    As of June 30, 2026, our management, with the participation of our Chief Executive Officer, who is also serving as Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) using the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control—Integrated Framework (2013 Framework). Our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. As previously reported in our Annual Report on Form 10-K filed on March 16, 2026, we identified a material weakness in our internal control over financial reporting. Because this material weakness remained unremediated as of June 30, 2026, management concluded that our disclosure controls and procedures were not effective as of that date. Management, with the oversight of the Audit Committee, is implementing a remediation plan that includes additional training, improvement of controls, and engagement of third party technical accounting resources. The material weakness will not be considered to be remediated until the applicable controls have operated for a sufficient period of time and management has concluded, through testing, that they are operating effectively.

    From the 10-Q filed 12 August 2026, Part I, Item 4. Controls and Procedures. Read it in the filing

A 10-K is the yearly report every US company files with the SEC. An 8-K is a short notice of a big event.

What could go wrong

  • Profits run ahead of cash.

Whether the price already reflects the risks is what the deep dive is for.

The deep dive

Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.

  • What the business is worth, as a range, and the margin of safety at today’s price
  • Prices to start buying, buy, and buy hard
  • The three things that would make this a mistake
  • Every number footnoted to the filing it came from
Create a free account to run it

Your first deep dive is free.

What a finished deep dive looks like

Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.